Hospital

The PRIMA study evaluated the efficacy and safety of niraparib therapy after response to platinum-based chemotherapy in patients with newly-diagnosed ovarian cancer.

At the ESMO Congress 2019, Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital, discussed the role of oncology pharmacists in managing the treatment of patients with ovarian cancer.

New data presented at the ESMO Congress 2019 showed that a 2-drug immunotherapy combination improved overall survival in patients with advanced non-small cell lung cancer.

Late-breaking data from the ESMO Congress 2019 demonstrate osimertinib’s superiority to older generation EGFR tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer.

At ESMO Congress 2019, Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital, discussed the latest practice-changing clinical data results involving PARP inhibitor therapy in ovarian cancer.

Five-year overall survival rates in patients with melanoma were 52% for nivolumab plus ipilimumab, 44% for nivolumab, and 26% for ipilimumab.  

Daratumumab was approved based on results from part one of the Phase III CASSIOPEIA study.

The European Society for Medical Oncology (ESMO) Congress 2019 will be taking place September 27 to October 1 in Barcelona, Spain, and Pharmacy Times® and Specialty Pharmacy Times® will be on location delivering coverage.

The postponement of USP chapters , , and was applauded by the International Academy of Compounding Pharmacists.

An upcoming webinar by Trellis Rx on Wednesday, September 18, will offer a firsthand look into how to accelerate the growth of your specialty pharmacy program by building strong provider partnerships.

With rapid growth, health system specialty pharmacies are more than likely to run into several operational pain points.

With specialty pharmacy emerging as the fastest growing segment of the pharmacy industry, health systems have to address a key question: can you scale for it?

Acetaminophen-related overdose continues to be a leading cause of emergency deparment visits and hospitalizations and remains the leading cause of drug-induced acute liver failure in the United States.

Community Pharmacy Consultant Bruce Kneeland and Kevin DeMass, RPh, President of Apothecary Shoppe, Salt Lake City, UT, discuss how pharmacy works with hospitals to improve outcomes for patients.

The Neostigmine Methylsulfate Injection is the first manufacturer-prepared, ready-to-administer prefilled syringe on the market.

Ali McBride, PharmD, MS, BCPS, BCOP, explains what strategies can help ensure patients are adherent to oral chemotherapy regimens.

Nancy Egerton, PharmD, BCOP, discusses the pharmacist's role in oncology care.

Three female leaders in pharmacy discuss the changes in this industry.

Julianne Orr, PharmD, discusses how pharmacists can help patients transitioning from infusion chemotherapy products to oral agents.

Over the years, a number of landmark clinical studies on the management of AF have been published, sharping how patients are treated. Here are 4 that every pharmacist should know about.

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival (PFS) compared with chemotherapy in treatment-naïve patients with high tumor mutation burden (TMB) non–small cell lung cancer (NSCLC).

The Institute for Safe Medication Practices recently added new best practices for improving patient safety in hospitals.

Pharmacists are the crux of successful care transitions between hospitals and post-acute care facilities.

Black children with severe pain are less likely to receive opioids in emergency rooms than white children.

The placebo effect is growing stronger in US clinical trials for chronic pain medications.

Citing a rare yet serious risk of slowed breathing, the FDA is evaluating the use of the opioid pain medication tramadol (Ultram, Ultram ER, Conzip) in the pediatric population.

Pregabalin and gabapentin are often considered first-line treatments for various neuropathic pain syndromes, generally irrespective of cause.